SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Provectus Pharmaceuticals Inc.
PVCT 0.06400.0%Nov 7 9:30 AM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: boomertree21/30/2014 10:09:24 AM
   of 13111
 
Pharmaceutical Firm Eyes Aggressive Push To Fill Gap Due To Patent Loss.

Reuters (1/30, Pierson) reports about Eli Lilly’s plans for an aggressive push to counter loss of billions of dollars in revenue due to end of patent protection for major therapies such as Zyprexa (olanzapine) for schizophrenia. Co-CEO John Lechleiter told Reuters that he sees promise of growth in treatments for diabetes and cancer that are awaiting approval, as well as boosting of sales of animal-health products and drugs in China and Japan.



Swiss Pharmaceutical Firm Sees Profit Up In 2014 Over New Cancer Medications.

Bloomberg News (1/30, Kresge) reports Roche Holding AG said it expects “low to mid-single-digit percentage” rise in revenue and a jump in profit in 2014, citing sales boost due to its “biggest cancer drugs and a slate of new therapies.” Net income for 2013 climbed 18 percent to $12.7 billion. The Swiss firm is strengthening its portfolio with new products such as breast cancer medicine Kadcyla (ado-trastuzumab emtansine) and leukemia therapy Gazyva (obinutuzumab), both of which received regulatory nod in the US last year. The company, however, “has been less successful with non-cancer drugs,” facing “its most recent setback last week with the failure of schizophrenia medicine bitopertin in a pair of final-stage patient trials,” Bloomberg said.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext